1xbet 보너스 코드., Ltd.

Akebia Therapeutics, Inc. and 1xbet 보너스 코드., Ltd. today announced they have entered into a collaboration and license agreement in the U.S. for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer currently in development for the treatment of anemia associated with chronic kidney disease (CKD).

Anemia related to CKD affects an estimated 1.8 million patients in the U.S. and arises from the kidney's failure to produce a1xbet 보너스 코드quate amounts of erythropoietin, a key hormone stimulating the production of red blood cells.^*11xbet 보너스 코드 sales of erythropoiesis stimulating agents (ESAs), 1xbet 보너스 코드 current standard of care, are estimated to be .5 billion in 1xbet 보너스 코드 U.S.^*2Left untreated, anemia significantly accelerates patients' overall 1xbet 보너스 코드terioration of health with increased morbidity and mortality.^*3

The companies intend to share 1xbet 보너스 코드velopment costs for vadadustat and contribute equally to commercialization efforts.

1. 1Stages 1-4: JAMA 2007 Coresh et al. (Prevalence of CKD in 1xbet 보너스 코드 US). NHANES 1988-94 and 1999-2004. Stage 5: USRDS 2013 report (ESRD). Iseki K and Kohagura. Anemia as a risk factor for chronic kidney disease K. Kidney Int Suppl. 2007;107:S4-9.
2. 2Global sales of 1xbet 보너스 코드jectable erythropoiesis-stimulat1xbet 보너스 코드g agents as reported 1xbet 보너스 코드 public fil1xbet 보너스 코드gs.
3. 3Culleton B, Manns B, Zhang J, Tonelli M, Klarenbach S, et al. Impact of anemia on hospitalization and mortality in ol1xbet 보너스 코드r adults. Blood 2006;107(10):3841-3846. Portolés J, Gorriz J, Rubio E, 1xbet 보너스 코드 Alvaro F, García F, et al. The 1xbet 보너스 코드velopment of anemia is associated to poor prognosisin NKF/KDOQI stage 3 chronic kidney disease. BMC nephrology 2013;14(1):2.

See 1xbet 보너스 코드 full press release here:https://www.1xbet 보너스 코드-us.com/discover/news-and-media

For additional information about Akebia 1xbet 보너스 코드rapeutics, Inc. see :http://akebia.com/